Retatrutide (LY3437943) represents the next frontier of incretin-based metabolic research. Where semaglutide targets GLP-1 receptors alone, and tirzepatide adds GIP, retatrutide simultaneously agonizes all three incretin and glucagon receptors — GLP-1R, GIPR, and GcgR — creating a uniquely powerful metabolic phenotype in research subjects.
Background: The Incretin System
Incretins are gut-derived hormones released in response to food intake that amplify insulin secretion. The two major incretins are:
GLP-1 (Glucagon-Like Peptide-1): Released from L-cells in the ileum. Stimulates insulin secretion, inhibits glucagon, slows gastric emptying, and reduces appetite. The target of semaglutide (Ozempic/Wegovy).
GIP (Glucose-dependent Insulinotropic Polypeptide): Released from K-cells in the duodenum. Potentiates GLP-1's insulin effects and plays a role in fat storage regulation. Added in tirzepatide (Mounjaro).
Glucagon: Produced by pancreatic alpha cells. Primarily raises blood glucose but also promotes fatty acid oxidation in the liver. Counterintuitively, glucagon receptor agonism in combination with GLP-1/GIP agonism has shown synergistic metabolic benefits — particularly for fatty liver disease and energy expenditure.
Retatrutide's Mechanism
Retatrutide is a 36-amino acid peptide with a C18 fatty acid chain attached for albumin binding, extending its half-life to approximately one week — suitable for once-weekly dosing in research protocols.
The triple agonism creates a convergent metabolic state: - GLP-1R activation → reduced appetite, slower gastric emptying, improved insulin sensitivity - GIPR activation → enhanced insulin amplification, potentially favorable effects on adipocyte function - GcgR activation → increased hepatic glucose production (offset by the other two axes), increased energy expenditure via thermogenesis, and accelerated fatty acid oxidation
The net effect in well-controlled preclinical and early clinical models has been dramatically greater weight reduction than single or dual agonists, along with improvements in liver fat, triglycerides, and markers of NASH.
Phase 2 Trial Data
The Phase 2 TRIUMPH trial (Eli Lilly, 2023) published results that reverberated through the metabolic research community:
- At 48 weeks, the highest dose cohort (12mg weekly) achieved ~24.2% mean body weight reduction — surpassing any prior agent in this class
- Significant dose-dependent reductions in liver fat content (by MRI-PDFF)
- Improvements in fasting glucose, triglycerides, and blood pressure
- Tolerability profile consistent with the GLP-1 agonist class (primarily GI side effects — nausea, vomiting, diarrhea)
These results propelled retatrutide into Phase 3 trials, with results anticipated in 2025-2026.
Research Significance
Beyond weight reduction, retatrutide is of significant interest as a research tool for: - Studying the relative contributions of each incretin axis to metabolic outcomes - NASH (non-alcoholic steatohepatitis) models — liver fat reduction exceeds what is seen with GLP-1 alone - Energy expenditure research — the glucagon component drives thermogenesis that pure GLP-1 agonists do not - Combination therapy research — understanding interaction effects with other metabolic agents
As a research peptide, retatrutide provides investigators access to triple-agonist biology before regulatory approval makes it commercially available.
Published References
Research Use Only. All content is for informational and educational purposes regarding preclinical research. None of the compounds discussed have been approved by the FDA for human therapeutic use. This information does not constitute medical advice.